PMC:7560808 / 4656-6755 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid_Glycan-Motif-Structure

    {"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T1","span":{"begin":259,"end":262},"obj":"https://glytoucan.org/Structures/Glycans/G00063MO"}],"text":"Characteristic Results\nNumber of patients 19\nAge, yr, median (interquartile range) 57 (45–69)\nSex, n (%)  \n M 18 (95)\n F 1 (5)\nBMI, kg/m2, median (interquartile range) 27.8 (26.2–33.5)\nComorbidities, n (%)  \n Asthma 1 (5)\n HTN 10 (53)\n CHF 2 (11)\n CAD 1 (5)\n Diabetes 5 (26)\n CKD 1 (5)\n Obesity 7 (37)\n Malignancy 2 (11)\n Immunosuppression 2 (11)\nInvasive ventilation, n (%) 19 (100)\nTime from hospital to ICU admission, d, median (interquartile range) 0 (0–2)\nTime from ICU admission to invasive ventilation, d, median (interquartile range) 0 (0–0)\nRespirator parameters, median (interquartile range)  \n FiO2, % 50 (30–60)\n PEEP, mbar 12 (12–15)\n Pplat, mbar 27 (23–30)\nOxygenation index (PaO2/FiO2), mm Hg, median (interquartile range) 173 (152–260)\nPaCO2, mm Hg, median (interquartile range) 46 (40–51)\npH, median (interquartile range) 7.36 (7.32–7.41)\nLactate, mmol/L, median (interquartile range) 1.6 (1.5–2.9)\nVasopressor, n (%) 16 (84.2)\nNorepinephrine dose, μg/kg/min, median (interquartile range) 0.083 (0.019–0.182)\nRenal replacement therapy, n (%) 3 (16)\nvv-ECMO support, n (%) 2 (11)\nSOFA score, points, median (interquartile range) 11 (9–14)\nOrgan-specific failures, n (%)  \n Respiratory (PaO2/FiO2 \u003c 300) 19 (100)\n Coagulation (thrombocytes \u003c 100) 1 (5)\n Liver (bilirubin \u003e 33 μmol/L) 1 (5)\n Cardiovascular (dobutamine or norepinephrine) 16 (84)\n Neurological (GCS \u003c 13) 19 (100)\n Renal (creatinine \u003e 170 μmol/L) 4 (21)\nLab, median (interquartile range)  \n CRP (normal: \u003c5), mg/L 174 (121–203)\n PCT normal: \u003c0.5), μg/L 3.8 (0.5–10.9)\n IL-6 (normal: \u003c7), ng/L 272 (142–541)\n LDH (normal: \u003c248), U/L 548 (384–657)\n D-Dimer (normal: \u003c0.5), mg/L 3.56 (0.84–8.88)\n Troponin T (normal: \u003c14), ng/L 17 (11–23)\n NT-proBNP (normal: \u003c86), ng/L 260 (82–1108)\nFurther clinical course, n (%)  \n Prone position 19 (100)\n Inhaled NO 4 (21)\n vv-ECMO 7 (37)\n Renal replacement therapy 8 (42)\n Septic shock 10 (53)\n Died by end of observation period 3 (16)\n Still dependent on critical care 6 (32)\n Still dependent on mechanical ventilation 2 (11)"}

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T24","span":{"begin":974,"end":988},"obj":"Body_part"},{"id":"T25","span":{"begin":1188,"end":1193},"obj":"Body_part"},{"id":"T26","span":{"begin":1277,"end":1289},"obj":"Body_part"},{"id":"T27","span":{"begin":1305,"end":1310},"obj":"Body_part"},{"id":"T28","span":{"begin":1373,"end":1387},"obj":"Body_part"},{"id":"T29","span":{"begin":1720,"end":1730},"obj":"Body_part"},{"id":"T30","span":{"begin":1720,"end":1728},"obj":"Body_part"}],"attributes":[{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma61799"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma62851"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma61799"},{"id":"A29","pred":"fma_id","subj":"T29","obj":"http://purl.org/sig/ont/fma/fma67900"},{"id":"A30","pred":"fma_id","subj":"T30","obj":"http://purl.org/sig/ont/fma/fma62338"}],"text":"Characteristic Results\nNumber of patients 19\nAge, yr, median (interquartile range) 57 (45–69)\nSex, n (%)  \n M 18 (95)\n F 1 (5)\nBMI, kg/m2, median (interquartile range) 27.8 (26.2–33.5)\nComorbidities, n (%)  \n Asthma 1 (5)\n HTN 10 (53)\n CHF 2 (11)\n CAD 1 (5)\n Diabetes 5 (26)\n CKD 1 (5)\n Obesity 7 (37)\n Malignancy 2 (11)\n Immunosuppression 2 (11)\nInvasive ventilation, n (%) 19 (100)\nTime from hospital to ICU admission, d, median (interquartile range) 0 (0–2)\nTime from ICU admission to invasive ventilation, d, median (interquartile range) 0 (0–0)\nRespirator parameters, median (interquartile range)  \n FiO2, % 50 (30–60)\n PEEP, mbar 12 (12–15)\n Pplat, mbar 27 (23–30)\nOxygenation index (PaO2/FiO2), mm Hg, median (interquartile range) 173 (152–260)\nPaCO2, mm Hg, median (interquartile range) 46 (40–51)\npH, median (interquartile range) 7.36 (7.32–7.41)\nLactate, mmol/L, median (interquartile range) 1.6 (1.5–2.9)\nVasopressor, n (%) 16 (84.2)\nNorepinephrine dose, μg/kg/min, median (interquartile range) 0.083 (0.019–0.182)\nRenal replacement therapy, n (%) 3 (16)\nvv-ECMO support, n (%) 2 (11)\nSOFA score, points, median (interquartile range) 11 (9–14)\nOrgan-specific failures, n (%)  \n Respiratory (PaO2/FiO2 \u003c 300) 19 (100)\n Coagulation (thrombocytes \u003c 100) 1 (5)\n Liver (bilirubin \u003e 33 μmol/L) 1 (5)\n Cardiovascular (dobutamine or norepinephrine) 16 (84)\n Neurological (GCS \u003c 13) 19 (100)\n Renal (creatinine \u003e 170 μmol/L) 4 (21)\nLab, median (interquartile range)  \n CRP (normal: \u003c5), mg/L 174 (121–203)\n PCT normal: \u003c0.5), μg/L 3.8 (0.5–10.9)\n IL-6 (normal: \u003c7), ng/L 272 (142–541)\n LDH (normal: \u003c248), U/L 548 (384–657)\n D-Dimer (normal: \u003c0.5), mg/L 3.56 (0.84–8.88)\n Troponin T (normal: \u003c14), ng/L 17 (11–23)\n NT-proBNP (normal: \u003c86), ng/L 260 (82–1108)\nFurther clinical course, n (%)  \n Prone position 19 (100)\n Inhaled NO 4 (21)\n vv-ECMO 7 (37)\n Renal replacement therapy 8 (42)\n Septic shock 10 (53)\n Died by end of observation period 3 (16)\n Still dependent on critical care 6 (32)\n Still dependent on mechanical ventilation 2 (11)"}

    LitCovid-PD-UBERON

    {"project":"LitCovid-PD-UBERON","denotations":[{"id":"T8","span":{"begin":1188,"end":1193},"obj":"Body_part"},{"id":"T9","span":{"begin":1305,"end":1310},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"Characteristic Results\nNumber of patients 19\nAge, yr, median (interquartile range) 57 (45–69)\nSex, n (%)  \n M 18 (95)\n F 1 (5)\nBMI, kg/m2, median (interquartile range) 27.8 (26.2–33.5)\nComorbidities, n (%)  \n Asthma 1 (5)\n HTN 10 (53)\n CHF 2 (11)\n CAD 1 (5)\n Diabetes 5 (26)\n CKD 1 (5)\n Obesity 7 (37)\n Malignancy 2 (11)\n Immunosuppression 2 (11)\nInvasive ventilation, n (%) 19 (100)\nTime from hospital to ICU admission, d, median (interquartile range) 0 (0–2)\nTime from ICU admission to invasive ventilation, d, median (interquartile range) 0 (0–0)\nRespirator parameters, median (interquartile range)  \n FiO2, % 50 (30–60)\n PEEP, mbar 12 (12–15)\n Pplat, mbar 27 (23–30)\nOxygenation index (PaO2/FiO2), mm Hg, median (interquartile range) 173 (152–260)\nPaCO2, mm Hg, median (interquartile range) 46 (40–51)\npH, median (interquartile range) 7.36 (7.32–7.41)\nLactate, mmol/L, median (interquartile range) 1.6 (1.5–2.9)\nVasopressor, n (%) 16 (84.2)\nNorepinephrine dose, μg/kg/min, median (interquartile range) 0.083 (0.019–0.182)\nRenal replacement therapy, n (%) 3 (16)\nvv-ECMO support, n (%) 2 (11)\nSOFA score, points, median (interquartile range) 11 (9–14)\nOrgan-specific failures, n (%)  \n Respiratory (PaO2/FiO2 \u003c 300) 19 (100)\n Coagulation (thrombocytes \u003c 100) 1 (5)\n Liver (bilirubin \u003e 33 μmol/L) 1 (5)\n Cardiovascular (dobutamine or norepinephrine) 16 (84)\n Neurological (GCS \u003c 13) 19 (100)\n Renal (creatinine \u003e 170 μmol/L) 4 (21)\nLab, median (interquartile range)  \n CRP (normal: \u003c5), mg/L 174 (121–203)\n PCT normal: \u003c0.5), μg/L 3.8 (0.5–10.9)\n IL-6 (normal: \u003c7), ng/L 272 (142–541)\n LDH (normal: \u003c248), U/L 548 (384–657)\n D-Dimer (normal: \u003c0.5), mg/L 3.56 (0.84–8.88)\n Troponin T (normal: \u003c14), ng/L 17 (11–23)\n NT-proBNP (normal: \u003c86), ng/L 260 (82–1108)\nFurther clinical course, n (%)  \n Prone position 19 (100)\n Inhaled NO 4 (21)\n vv-ECMO 7 (37)\n Renal replacement therapy 8 (42)\n Septic shock 10 (53)\n Died by end of observation period 3 (16)\n Still dependent on critical care 6 (32)\n Still dependent on mechanical ventilation 2 (11)"}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T27","span":{"begin":217,"end":223},"obj":"Disease"},{"id":"T28","span":{"begin":232,"end":235},"obj":"Disease"},{"id":"T29","span":{"begin":246,"end":249},"obj":"Disease"},{"id":"T30","span":{"begin":259,"end":262},"obj":"Disease"},{"id":"T32","span":{"begin":271,"end":279},"obj":"Disease"},{"id":"T33","span":{"begin":289,"end":292},"obj":"Disease"},{"id":"T34","span":{"begin":301,"end":308},"obj":"Disease"},{"id":"T35","span":{"begin":1551,"end":1554},"obj":"Disease"}],"attributes":[{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0005009"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0005010"},{"id":"A31","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0018922"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0005300"},{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0011122"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0008296"},{"id":"A36","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0015104"}],"text":"Characteristic Results\nNumber of patients 19\nAge, yr, median (interquartile range) 57 (45–69)\nSex, n (%)  \n M 18 (95)\n F 1 (5)\nBMI, kg/m2, median (interquartile range) 27.8 (26.2–33.5)\nComorbidities, n (%)  \n Asthma 1 (5)\n HTN 10 (53)\n CHF 2 (11)\n CAD 1 (5)\n Diabetes 5 (26)\n CKD 1 (5)\n Obesity 7 (37)\n Malignancy 2 (11)\n Immunosuppression 2 (11)\nInvasive ventilation, n (%) 19 (100)\nTime from hospital to ICU admission, d, median (interquartile range) 0 (0–2)\nTime from ICU admission to invasive ventilation, d, median (interquartile range) 0 (0–0)\nRespirator parameters, median (interquartile range)  \n FiO2, % 50 (30–60)\n PEEP, mbar 12 (12–15)\n Pplat, mbar 27 (23–30)\nOxygenation index (PaO2/FiO2), mm Hg, median (interquartile range) 173 (152–260)\nPaCO2, mm Hg, median (interquartile range) 46 (40–51)\npH, median (interquartile range) 7.36 (7.32–7.41)\nLactate, mmol/L, median (interquartile range) 1.6 (1.5–2.9)\nVasopressor, n (%) 16 (84.2)\nNorepinephrine dose, μg/kg/min, median (interquartile range) 0.083 (0.019–0.182)\nRenal replacement therapy, n (%) 3 (16)\nvv-ECMO support, n (%) 2 (11)\nSOFA score, points, median (interquartile range) 11 (9–14)\nOrgan-specific failures, n (%)  \n Respiratory (PaO2/FiO2 \u003c 300) 19 (100)\n Coagulation (thrombocytes \u003c 100) 1 (5)\n Liver (bilirubin \u003e 33 μmol/L) 1 (5)\n Cardiovascular (dobutamine or norepinephrine) 16 (84)\n Neurological (GCS \u003c 13) 19 (100)\n Renal (creatinine \u003e 170 μmol/L) 4 (21)\nLab, median (interquartile range)  \n CRP (normal: \u003c5), mg/L 174 (121–203)\n PCT normal: \u003c0.5), μg/L 3.8 (0.5–10.9)\n IL-6 (normal: \u003c7), ng/L 272 (142–541)\n LDH (normal: \u003c248), U/L 548 (384–657)\n D-Dimer (normal: \u003c0.5), mg/L 3.56 (0.84–8.88)\n Troponin T (normal: \u003c14), ng/L 17 (11–23)\n NT-proBNP (normal: \u003c86), ng/L 260 (82–1108)\nFurther clinical course, n (%)  \n Prone position 19 (100)\n Inhaled NO 4 (21)\n vv-ECMO 7 (37)\n Renal replacement therapy 8 (42)\n Septic shock 10 (53)\n Died by end of observation period 3 (16)\n Still dependent on critical care 6 (32)\n Still dependent on mechanical ventilation 2 (11)"}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T28","span":{"begin":90,"end":92},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T29","span":{"begin":115,"end":117},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T30","span":{"begin":124,"end":128},"obj":"http://purl.obolibrary.org/obo/CLO_0002960"},{"id":"T31","span":{"begin":254,"end":256},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T32","span":{"begin":333,"end":335},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T33","span":{"begin":360,"end":362},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T34","span":{"begin":684,"end":686},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T35","span":{"begin":1124,"end":1126},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T36","span":{"begin":1178,"end":1180},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T37","span":{"begin":1188,"end":1193},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T38","span":{"begin":1305,"end":1310},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T39","span":{"begin":1305,"end":1310},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T40","span":{"begin":1541,"end":1544},"obj":"http://purl.obolibrary.org/obo/CLO_0001053"},{"id":"T41","span":{"begin":1545,"end":1548},"obj":"http://purl.obolibrary.org/obo/CLO_0001180"},{"id":"T42","span":{"begin":1657,"end":1660},"obj":"http://purl.obolibrary.org/obo/CLO_0001414"},{"id":"T43","span":{"begin":1756,"end":1758},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T44","span":{"begin":2096,"end":2098},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"}],"text":"Characteristic Results\nNumber of patients 19\nAge, yr, median (interquartile range) 57 (45–69)\nSex, n (%)  \n M 18 (95)\n F 1 (5)\nBMI, kg/m2, median (interquartile range) 27.8 (26.2–33.5)\nComorbidities, n (%)  \n Asthma 1 (5)\n HTN 10 (53)\n CHF 2 (11)\n CAD 1 (5)\n Diabetes 5 (26)\n CKD 1 (5)\n Obesity 7 (37)\n Malignancy 2 (11)\n Immunosuppression 2 (11)\nInvasive ventilation, n (%) 19 (100)\nTime from hospital to ICU admission, d, median (interquartile range) 0 (0–2)\nTime from ICU admission to invasive ventilation, d, median (interquartile range) 0 (0–0)\nRespirator parameters, median (interquartile range)  \n FiO2, % 50 (30–60)\n PEEP, mbar 12 (12–15)\n Pplat, mbar 27 (23–30)\nOxygenation index (PaO2/FiO2), mm Hg, median (interquartile range) 173 (152–260)\nPaCO2, mm Hg, median (interquartile range) 46 (40–51)\npH, median (interquartile range) 7.36 (7.32–7.41)\nLactate, mmol/L, median (interquartile range) 1.6 (1.5–2.9)\nVasopressor, n (%) 16 (84.2)\nNorepinephrine dose, μg/kg/min, median (interquartile range) 0.083 (0.019–0.182)\nRenal replacement therapy, n (%) 3 (16)\nvv-ECMO support, n (%) 2 (11)\nSOFA score, points, median (interquartile range) 11 (9–14)\nOrgan-specific failures, n (%)  \n Respiratory (PaO2/FiO2 \u003c 300) 19 (100)\n Coagulation (thrombocytes \u003c 100) 1 (5)\n Liver (bilirubin \u003e 33 μmol/L) 1 (5)\n Cardiovascular (dobutamine or norepinephrine) 16 (84)\n Neurological (GCS \u003c 13) 19 (100)\n Renal (creatinine \u003e 170 μmol/L) 4 (21)\nLab, median (interquartile range)  \n CRP (normal: \u003c5), mg/L 174 (121–203)\n PCT normal: \u003c0.5), μg/L 3.8 (0.5–10.9)\n IL-6 (normal: \u003c7), ng/L 272 (142–541)\n LDH (normal: \u003c248), U/L 548 (384–657)\n D-Dimer (normal: \u003c0.5), mg/L 3.56 (0.84–8.88)\n Troponin T (normal: \u003c14), ng/L 17 (11–23)\n NT-proBNP (normal: \u003c86), ng/L 260 (82–1108)\nFurther clinical course, n (%)  \n Prone position 19 (100)\n Inhaled NO 4 (21)\n vv-ECMO 7 (37)\n Renal replacement therapy 8 (42)\n Septic shock 10 (53)\n Died by end of observation period 3 (16)\n Still dependent on critical care 6 (32)\n Still dependent on mechanical ventilation 2 (11)"}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T11","span":{"begin":647,"end":651},"obj":"Chemical"},{"id":"T13","span":{"begin":729,"end":731},"obj":"Chemical"},{"id":"T15","span":{"begin":787,"end":789},"obj":"Chemical"},{"id":"T17","span":{"begin":974,"end":988},"obj":"Chemical"},{"id":"T18","span":{"begin":1312,"end":1321},"obj":"Chemical"},{"id":"T19","span":{"begin":1359,"end":1369},"obj":"Chemical"},{"id":"T20","span":{"begin":1373,"end":1387},"obj":"Chemical"},{"id":"T22","span":{"begin":1441,"end":1451},"obj":"Chemical"},{"id":"T23","span":{"begin":1592,"end":1594},"obj":"Chemical"}],"attributes":[{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_53359"},{"id":"A12","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_60683"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_16170"},{"id":"A14","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_25195"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_16170"},{"id":"A16","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_25195"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_18357"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_16990"},{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_4670"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_18357"},{"id":"A21","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_33569"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_16737"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A24","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Characteristic Results\nNumber of patients 19\nAge, yr, median (interquartile range) 57 (45–69)\nSex, n (%)  \n M 18 (95)\n F 1 (5)\nBMI, kg/m2, median (interquartile range) 27.8 (26.2–33.5)\nComorbidities, n (%)  \n Asthma 1 (5)\n HTN 10 (53)\n CHF 2 (11)\n CAD 1 (5)\n Diabetes 5 (26)\n CKD 1 (5)\n Obesity 7 (37)\n Malignancy 2 (11)\n Immunosuppression 2 (11)\nInvasive ventilation, n (%) 19 (100)\nTime from hospital to ICU admission, d, median (interquartile range) 0 (0–2)\nTime from ICU admission to invasive ventilation, d, median (interquartile range) 0 (0–0)\nRespirator parameters, median (interquartile range)  \n FiO2, % 50 (30–60)\n PEEP, mbar 12 (12–15)\n Pplat, mbar 27 (23–30)\nOxygenation index (PaO2/FiO2), mm Hg, median (interquartile range) 173 (152–260)\nPaCO2, mm Hg, median (interquartile range) 46 (40–51)\npH, median (interquartile range) 7.36 (7.32–7.41)\nLactate, mmol/L, median (interquartile range) 1.6 (1.5–2.9)\nVasopressor, n (%) 16 (84.2)\nNorepinephrine dose, μg/kg/min, median (interquartile range) 0.083 (0.019–0.182)\nRenal replacement therapy, n (%) 3 (16)\nvv-ECMO support, n (%) 2 (11)\nSOFA score, points, median (interquartile range) 11 (9–14)\nOrgan-specific failures, n (%)  \n Respiratory (PaO2/FiO2 \u003c 300) 19 (100)\n Coagulation (thrombocytes \u003c 100) 1 (5)\n Liver (bilirubin \u003e 33 μmol/L) 1 (5)\n Cardiovascular (dobutamine or norepinephrine) 16 (84)\n Neurological (GCS \u003c 13) 19 (100)\n Renal (creatinine \u003e 170 μmol/L) 4 (21)\nLab, median (interquartile range)  \n CRP (normal: \u003c5), mg/L 174 (121–203)\n PCT normal: \u003c0.5), μg/L 3.8 (0.5–10.9)\n IL-6 (normal: \u003c7), ng/L 272 (142–541)\n LDH (normal: \u003c248), U/L 548 (384–657)\n D-Dimer (normal: \u003c0.5), mg/L 3.56 (0.84–8.88)\n Troponin T (normal: \u003c14), ng/L 17 (11–23)\n NT-proBNP (normal: \u003c86), ng/L 260 (82–1108)\nFurther clinical course, n (%)  \n Prone position 19 (100)\n Inhaled NO 4 (21)\n vv-ECMO 7 (37)\n Renal replacement therapy 8 (42)\n Septic shock 10 (53)\n Died by end of observation period 3 (16)\n Still dependent on critical care 6 (32)\n Still dependent on mechanical ventilation 2 (11)"}

    LitCovid-PD-GO-BP

    {"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T6","span":{"begin":1264,"end":1275},"obj":"http://purl.obolibrary.org/obo/GO_0050817"}],"text":"Characteristic Results\nNumber of patients 19\nAge, yr, median (interquartile range) 57 (45–69)\nSex, n (%)  \n M 18 (95)\n F 1 (5)\nBMI, kg/m2, median (interquartile range) 27.8 (26.2–33.5)\nComorbidities, n (%)  \n Asthma 1 (5)\n HTN 10 (53)\n CHF 2 (11)\n CAD 1 (5)\n Diabetes 5 (26)\n CKD 1 (5)\n Obesity 7 (37)\n Malignancy 2 (11)\n Immunosuppression 2 (11)\nInvasive ventilation, n (%) 19 (100)\nTime from hospital to ICU admission, d, median (interquartile range) 0 (0–2)\nTime from ICU admission to invasive ventilation, d, median (interquartile range) 0 (0–0)\nRespirator parameters, median (interquartile range)  \n FiO2, % 50 (30–60)\n PEEP, mbar 12 (12–15)\n Pplat, mbar 27 (23–30)\nOxygenation index (PaO2/FiO2), mm Hg, median (interquartile range) 173 (152–260)\nPaCO2, mm Hg, median (interquartile range) 46 (40–51)\npH, median (interquartile range) 7.36 (7.32–7.41)\nLactate, mmol/L, median (interquartile range) 1.6 (1.5–2.9)\nVasopressor, n (%) 16 (84.2)\nNorepinephrine dose, μg/kg/min, median (interquartile range) 0.083 (0.019–0.182)\nRenal replacement therapy, n (%) 3 (16)\nvv-ECMO support, n (%) 2 (11)\nSOFA score, points, median (interquartile range) 11 (9–14)\nOrgan-specific failures, n (%)  \n Respiratory (PaO2/FiO2 \u003c 300) 19 (100)\n Coagulation (thrombocytes \u003c 100) 1 (5)\n Liver (bilirubin \u003e 33 μmol/L) 1 (5)\n Cardiovascular (dobutamine or norepinephrine) 16 (84)\n Neurological (GCS \u003c 13) 19 (100)\n Renal (creatinine \u003e 170 μmol/L) 4 (21)\nLab, median (interquartile range)  \n CRP (normal: \u003c5), mg/L 174 (121–203)\n PCT normal: \u003c0.5), μg/L 3.8 (0.5–10.9)\n IL-6 (normal: \u003c7), ng/L 272 (142–541)\n LDH (normal: \u003c248), U/L 548 (384–657)\n D-Dimer (normal: \u003c0.5), mg/L 3.56 (0.84–8.88)\n Troponin T (normal: \u003c14), ng/L 17 (11–23)\n NT-proBNP (normal: \u003c86), ng/L 260 (82–1108)\nFurther clinical course, n (%)  \n Prone position 19 (100)\n Inhaled NO 4 (21)\n vv-ECMO 7 (37)\n Renal replacement therapy 8 (42)\n Septic shock 10 (53)\n Died by end of observation period 3 (16)\n Still dependent on critical care 6 (32)\n Still dependent on mechanical ventilation 2 (11)"}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T37","span":{"begin":0,"end":23},"obj":"Sentence"},{"id":"T38","span":{"begin":24,"end":46},"obj":"Sentence"},{"id":"T39","span":{"begin":47,"end":96},"obj":"Sentence"},{"id":"T40","span":{"begin":97,"end":110},"obj":"Sentence"},{"id":"T41","span":{"begin":111,"end":122},"obj":"Sentence"},{"id":"T42","span":{"begin":123,"end":132},"obj":"Sentence"},{"id":"T43","span":{"begin":133,"end":191},"obj":"Sentence"},{"id":"T44","span":{"begin":192,"end":215},"obj":"Sentence"},{"id":"T45","span":{"begin":216,"end":230},"obj":"Sentence"},{"id":"T46","span":{"begin":231,"end":244},"obj":"Sentence"},{"id":"T47","span":{"begin":245,"end":257},"obj":"Sentence"},{"id":"T48","span":{"begin":258,"end":269},"obj":"Sentence"},{"id":"T49","span":{"begin":270,"end":287},"obj":"Sentence"},{"id":"T50","span":{"begin":288,"end":299},"obj":"Sentence"},{"id":"T51","span":{"begin":300,"end":316},"obj":"Sentence"},{"id":"T52","span":{"begin":317,"end":336},"obj":"Sentence"},{"id":"T53","span":{"begin":337,"end":363},"obj":"Sentence"},{"id":"T54","span":{"begin":364,"end":401},"obj":"Sentence"},{"id":"T55","span":{"begin":402,"end":479},"obj":"Sentence"},{"id":"T56","span":{"begin":480,"end":569},"obj":"Sentence"},{"id":"T57","span":{"begin":570,"end":624},"obj":"Sentence"},{"id":"T58","span":{"begin":625,"end":645},"obj":"Sentence"},{"id":"T59","span":{"begin":646,"end":669},"obj":"Sentence"},{"id":"T60","span":{"begin":670,"end":694},"obj":"Sentence"},{"id":"T61","span":{"begin":695,"end":776},"obj":"Sentence"},{"id":"T62","span":{"begin":777,"end":831},"obj":"Sentence"},{"id":"T63","span":{"begin":832,"end":882},"obj":"Sentence"},{"id":"T64","span":{"begin":883,"end":943},"obj":"Sentence"},{"id":"T65","span":{"begin":944,"end":973},"obj":"Sentence"},{"id":"T66","span":{"begin":974,"end":1055},"obj":"Sentence"},{"id":"T67","span":{"begin":1056,"end":1096},"obj":"Sentence"},{"id":"T68","span":{"begin":1097,"end":1127},"obj":"Sentence"},{"id":"T69","span":{"begin":1128,"end":1187},"obj":"Sentence"},{"id":"T70","span":{"begin":1188,"end":1221},"obj":"Sentence"},{"id":"T71","span":{"begin":1222,"end":1262},"obj":"Sentence"},{"id":"T72","span":{"begin":1263,"end":1303},"obj":"Sentence"},{"id":"T73","span":{"begin":1304,"end":1341},"obj":"Sentence"},{"id":"T74","span":{"begin":1342,"end":1397},"obj":"Sentence"},{"id":"T75","span":{"begin":1398,"end":1432},"obj":"Sentence"},{"id":"T76","span":{"begin":1433,"end":1473},"obj":"Sentence"},{"id":"T77","span":{"begin":1474,"end":1510},"obj":"Sentence"},{"id":"T78","span":{"begin":1511,"end":1549},"obj":"Sentence"},{"id":"T79","span":{"begin":1550,"end":1590},"obj":"Sentence"},{"id":"T80","span":{"begin":1591,"end":1630},"obj":"Sentence"},{"id":"T81","span":{"begin":1631,"end":1670},"obj":"Sentence"},{"id":"T82","span":{"begin":1671,"end":1718},"obj":"Sentence"},{"id":"T83","span":{"begin":1719,"end":1762},"obj":"Sentence"},{"id":"T84","span":{"begin":1763,"end":1808},"obj":"Sentence"},{"id":"T85","span":{"begin":1809,"end":1842},"obj":"Sentence"},{"id":"T86","span":{"begin":1843,"end":1868},"obj":"Sentence"},{"id":"T87","span":{"begin":1869,"end":1888},"obj":"Sentence"},{"id":"T88","span":{"begin":1889,"end":1905},"obj":"Sentence"},{"id":"T89","span":{"begin":1906,"end":1940},"obj":"Sentence"},{"id":"T90","span":{"begin":1941,"end":1963},"obj":"Sentence"},{"id":"T91","span":{"begin":1964,"end":2006},"obj":"Sentence"},{"id":"T92","span":{"begin":2007,"end":2048},"obj":"Sentence"},{"id":"T93","span":{"begin":2049,"end":2099},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Characteristic Results\nNumber of patients 19\nAge, yr, median (interquartile range) 57 (45–69)\nSex, n (%)  \n M 18 (95)\n F 1 (5)\nBMI, kg/m2, median (interquartile range) 27.8 (26.2–33.5)\nComorbidities, n (%)  \n Asthma 1 (5)\n HTN 10 (53)\n CHF 2 (11)\n CAD 1 (5)\n Diabetes 5 (26)\n CKD 1 (5)\n Obesity 7 (37)\n Malignancy 2 (11)\n Immunosuppression 2 (11)\nInvasive ventilation, n (%) 19 (100)\nTime from hospital to ICU admission, d, median (interquartile range) 0 (0–2)\nTime from ICU admission to invasive ventilation, d, median (interquartile range) 0 (0–0)\nRespirator parameters, median (interquartile range)  \n FiO2, % 50 (30–60)\n PEEP, mbar 12 (12–15)\n Pplat, mbar 27 (23–30)\nOxygenation index (PaO2/FiO2), mm Hg, median (interquartile range) 173 (152–260)\nPaCO2, mm Hg, median (interquartile range) 46 (40–51)\npH, median (interquartile range) 7.36 (7.32–7.41)\nLactate, mmol/L, median (interquartile range) 1.6 (1.5–2.9)\nVasopressor, n (%) 16 (84.2)\nNorepinephrine dose, μg/kg/min, median (interquartile range) 0.083 (0.019–0.182)\nRenal replacement therapy, n (%) 3 (16)\nvv-ECMO support, n (%) 2 (11)\nSOFA score, points, median (interquartile range) 11 (9–14)\nOrgan-specific failures, n (%)  \n Respiratory (PaO2/FiO2 \u003c 300) 19 (100)\n Coagulation (thrombocytes \u003c 100) 1 (5)\n Liver (bilirubin \u003e 33 μmol/L) 1 (5)\n Cardiovascular (dobutamine or norepinephrine) 16 (84)\n Neurological (GCS \u003c 13) 19 (100)\n Renal (creatinine \u003e 170 μmol/L) 4 (21)\nLab, median (interquartile range)  \n CRP (normal: \u003c5), mg/L 174 (121–203)\n PCT normal: \u003c0.5), μg/L 3.8 (0.5–10.9)\n IL-6 (normal: \u003c7), ng/L 272 (142–541)\n LDH (normal: \u003c248), U/L 548 (384–657)\n D-Dimer (normal: \u003c0.5), mg/L 3.56 (0.84–8.88)\n Troponin T (normal: \u003c14), ng/L 17 (11–23)\n NT-proBNP (normal: \u003c86), ng/L 260 (82–1108)\nFurther clinical course, n (%)  \n Prone position 19 (100)\n Inhaled NO 4 (21)\n vv-ECMO 7 (37)\n Renal replacement therapy 8 (42)\n Septic shock 10 (53)\n Died by end of observation period 3 (16)\n Still dependent on critical care 6 (32)\n Still dependent on mechanical ventilation 2 (11)"}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T2","span":{"begin":217,"end":223},"obj":"Phenotype"},{"id":"T3","span":{"begin":246,"end":249},"obj":"Phenotype"},{"id":"T4","span":{"begin":301,"end":308},"obj":"Phenotype"},{"id":"T5","span":{"begin":1949,"end":1954},"obj":"Phenotype"}],"attributes":[{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002099"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0001635"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0001513"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0031273"}],"text":"Characteristic Results\nNumber of patients 19\nAge, yr, median (interquartile range) 57 (45–69)\nSex, n (%)  \n M 18 (95)\n F 1 (5)\nBMI, kg/m2, median (interquartile range) 27.8 (26.2–33.5)\nComorbidities, n (%)  \n Asthma 1 (5)\n HTN 10 (53)\n CHF 2 (11)\n CAD 1 (5)\n Diabetes 5 (26)\n CKD 1 (5)\n Obesity 7 (37)\n Malignancy 2 (11)\n Immunosuppression 2 (11)\nInvasive ventilation, n (%) 19 (100)\nTime from hospital to ICU admission, d, median (interquartile range) 0 (0–2)\nTime from ICU admission to invasive ventilation, d, median (interquartile range) 0 (0–0)\nRespirator parameters, median (interquartile range)  \n FiO2, % 50 (30–60)\n PEEP, mbar 12 (12–15)\n Pplat, mbar 27 (23–30)\nOxygenation index (PaO2/FiO2), mm Hg, median (interquartile range) 173 (152–260)\nPaCO2, mm Hg, median (interquartile range) 46 (40–51)\npH, median (interquartile range) 7.36 (7.32–7.41)\nLactate, mmol/L, median (interquartile range) 1.6 (1.5–2.9)\nVasopressor, n (%) 16 (84.2)\nNorepinephrine dose, μg/kg/min, median (interquartile range) 0.083 (0.019–0.182)\nRenal replacement therapy, n (%) 3 (16)\nvv-ECMO support, n (%) 2 (11)\nSOFA score, points, median (interquartile range) 11 (9–14)\nOrgan-specific failures, n (%)  \n Respiratory (PaO2/FiO2 \u003c 300) 19 (100)\n Coagulation (thrombocytes \u003c 100) 1 (5)\n Liver (bilirubin \u003e 33 μmol/L) 1 (5)\n Cardiovascular (dobutamine or norepinephrine) 16 (84)\n Neurological (GCS \u003c 13) 19 (100)\n Renal (creatinine \u003e 170 μmol/L) 4 (21)\nLab, median (interquartile range)  \n CRP (normal: \u003c5), mg/L 174 (121–203)\n PCT normal: \u003c0.5), μg/L 3.8 (0.5–10.9)\n IL-6 (normal: \u003c7), ng/L 272 (142–541)\n LDH (normal: \u003c248), U/L 548 (384–657)\n D-Dimer (normal: \u003c0.5), mg/L 3.56 (0.84–8.88)\n Troponin T (normal: \u003c14), ng/L 17 (11–23)\n NT-proBNP (normal: \u003c86), ng/L 260 (82–1108)\nFurther clinical course, n (%)  \n Prone position 19 (100)\n Inhaled NO 4 (21)\n vv-ECMO 7 (37)\n Renal replacement therapy 8 (42)\n Septic shock 10 (53)\n Died by end of observation period 3 (16)\n Still dependent on critical care 6 (32)\n Still dependent on mechanical ventilation 2 (11)"}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"157","span":{"begin":1512,"end":1515},"obj":"Gene"},{"id":"158","span":{"begin":1592,"end":1596},"obj":"Gene"},{"id":"159","span":{"begin":34,"end":42},"obj":"Species"},{"id":"160","span":{"begin":1441,"end":1451},"obj":"Chemical"},{"id":"161","span":{"begin":246,"end":249},"obj":"Disease"},{"id":"162","span":{"begin":271,"end":279},"obj":"Disease"},{"id":"163","span":{"begin":1942,"end":1954},"obj":"Disease"},{"id":"164","span":{"begin":1965,"end":1969},"obj":"Disease"},{"id":"165","span":{"begin":777,"end":782},"obj":"CellLine"}],"attributes":[{"id":"A157","pred":"tao:has_database_id","subj":"157","obj":"Gene:1401"},{"id":"A158","pred":"tao:has_database_id","subj":"158","obj":"Gene:3569"},{"id":"A159","pred":"tao:has_database_id","subj":"159","obj":"Tax:9606"},{"id":"A160","pred":"tao:has_database_id","subj":"160","obj":"MESH:D003404"},{"id":"A162","pred":"tao:has_database_id","subj":"162","obj":"MESH:D003920"},{"id":"A163","pred":"tao:has_database_id","subj":"163","obj":"MESH:D012772"},{"id":"A164","pred":"tao:has_database_id","subj":"164","obj":"MESH:D003643"},{"id":"A165","pred":"tao:has_database_id","subj":"165","obj":"CVCL:L340"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Characteristic Results\nNumber of patients 19\nAge, yr, median (interquartile range) 57 (45–69)\nSex, n (%)  \n M 18 (95)\n F 1 (5)\nBMI, kg/m2, median (interquartile range) 27.8 (26.2–33.5)\nComorbidities, n (%)  \n Asthma 1 (5)\n HTN 10 (53)\n CHF 2 (11)\n CAD 1 (5)\n Diabetes 5 (26)\n CKD 1 (5)\n Obesity 7 (37)\n Malignancy 2 (11)\n Immunosuppression 2 (11)\nInvasive ventilation, n (%) 19 (100)\nTime from hospital to ICU admission, d, median (interquartile range) 0 (0–2)\nTime from ICU admission to invasive ventilation, d, median (interquartile range) 0 (0–0)\nRespirator parameters, median (interquartile range)  \n FiO2, % 50 (30–60)\n PEEP, mbar 12 (12–15)\n Pplat, mbar 27 (23–30)\nOxygenation index (PaO2/FiO2), mm Hg, median (interquartile range) 173 (152–260)\nPaCO2, mm Hg, median (interquartile range) 46 (40–51)\npH, median (interquartile range) 7.36 (7.32–7.41)\nLactate, mmol/L, median (interquartile range) 1.6 (1.5–2.9)\nVasopressor, n (%) 16 (84.2)\nNorepinephrine dose, μg/kg/min, median (interquartile range) 0.083 (0.019–0.182)\nRenal replacement therapy, n (%) 3 (16)\nvv-ECMO support, n (%) 2 (11)\nSOFA score, points, median (interquartile range) 11 (9–14)\nOrgan-specific failures, n (%)  \n Respiratory (PaO2/FiO2 \u003c 300) 19 (100)\n Coagulation (thrombocytes \u003c 100) 1 (5)\n Liver (bilirubin \u003e 33 μmol/L) 1 (5)\n Cardiovascular (dobutamine or norepinephrine) 16 (84)\n Neurological (GCS \u003c 13) 19 (100)\n Renal (creatinine \u003e 170 μmol/L) 4 (21)\nLab, median (interquartile range)  \n CRP (normal: \u003c5), mg/L 174 (121–203)\n PCT normal: \u003c0.5), μg/L 3.8 (0.5–10.9)\n IL-6 (normal: \u003c7), ng/L 272 (142–541)\n LDH (normal: \u003c248), U/L 548 (384–657)\n D-Dimer (normal: \u003c0.5), mg/L 3.56 (0.84–8.88)\n Troponin T (normal: \u003c14), ng/L 17 (11–23)\n NT-proBNP (normal: \u003c86), ng/L 260 (82–1108)\nFurther clinical course, n (%)  \n Prone position 19 (100)\n Inhaled NO 4 (21)\n vv-ECMO 7 (37)\n Renal replacement therapy 8 (42)\n Septic shock 10 (53)\n Died by end of observation period 3 (16)\n Still dependent on critical care 6 (32)\n Still dependent on mechanical ventilation 2 (11)"}